Skip to main content

Market Research Outlook

MRO Tracker · Pharma

Who can sell which medicine in India, and from when. For 50 widely used, newly opened and soon to open molecules, this tracker shows the originator, the Indian patent position, which Indian companies make generics or biosimilars, whether the price is controlled, the approved uses, common side effects and the main trials behind each drug.

50molecules tracked
38with Indian generics or biosimilars on sale
9still patent protected
9under price control (NLEM 2022)

Download this tracker as Excel

MRO View: In India, patent expiry is the market event that matters. When semaglutide, empagliflozin and palbociclib went off patent, Indian makers launched within a day and prices fell sharply. For a company planning entry, the patent date, the makers already lined up and price control status say more than past sales.

Diabetes and obesity · Novo Nordisk (Ozempic, Rybelsus, Wegovy)

Semaglutide

India status
Generics launched
India timeline
Indian patent expired on 20 March 2026. Natco launched on day one at Rs 1,290 a month for multi dose vials.
Indian makers
Natco (with Eris marketing Sundae), Sun Pharma, Dr Reddy's, Zydus (Semaglyn, Mashema), Glenmark (Glipiq), Mankind (Samakind), Alkem, Torrent
Price control (NLEM 2022)
No
Approved uses
Type 2 diabetes; weight management (Wegovy)
Common side effects
Nausea, vomiting, diarrhoea, stomach pain, constipation. Label warnings on thyroid C cell tumours and pancreatitis.
Evidence base
SUSTAIN (diabetes), STEP (obesity), SELECT (heart outcomes)
MRO View: The day one price set the floor for the whole class. With seven or more makers, the fight moves to devices, doses and doctor reach, not price alone.

Diabetes and obesity · Eli Lilly (Mounjaro); Cipla sells a second brand, Yurpeak, made by Lilly

Tirzepatide

India status
Patent protected
India timeline
Lilly launched Mounjaro vials on 20 March 2025. CDSCO approved the KwikPen in June 2025 and it reached pharmacies nationwide in August 2025. Cipla launched Yurpeak on 10 December 2025.
Indian makers
None. Cipla markets Lilly made Yurpeak.
Price control (NLEM 2022)
No
Approved uses
Type 2 diabetes; chronic weight management
Common side effects
Nausea, diarrhoea, vomiting, constipation, reduced appetite. Label warning on thyroid C cell tumours.
Evidence base
SURPASS (diabetes), SURMOUNT (obesity)
MRO View: No generic route yet. Entry for others is through partnership with Lilly, as Cipla did, rather than competition.

Diabetes and obesity · Novo Nordisk (Victoza, Saxenda)

Liraglutide

India status
Generic approved
India timeline
Biocon received CDSCO approval for its generic in June 2025 under the 101 route, which recognises approvals from reference regulators.
Indian makers
Biocon (drug substance and product), launching through commercial partners
Price control (NLEM 2022)
No
Approved uses
Type 2 diabetes in adults and children aged 10 and above
Common side effects
Nausea, diarrhoea, vomiting, reduced appetite. Label warning on thyroid C cell tumours.
Evidence base
LEADER (heart outcomes), LEAD programme
MRO View: The 101 route shortened the path to approval. Daily liraglutide now competes with weekly semaglutide generics.

Diabetes and obesity · Boehringer Ingelheim (Jardiance)

Empagliflozin

India status
Generics launched
India timeline
Indian patent expired on 11 March 2025. Generic launches began the next day at prices about 80 to 90% below the brand.
Indian makers
Mankind (Empaglyde), Glenmark (Glempa), Alkem (Empanorm), USV (Xenia) and others; Torrent bought three Boehringer diabetes brands in December 2024
Price control (NLEM 2022)
No
Approved uses
Type 2 diabetes, heart failure, chronic kidney disease
Common side effects
Genital fungal infections, urinary tract infections, dehydration. Rare ketoacidosis.
Evidence base
EMPA-REG OUTCOME, EMPEROR-Reduced and EMPEROR-Preserved, EMPA-KIDNEY
MRO View: Heart and kidney labels widen use beyond diabetes clinics. Brand strength with cardiologists and nephrologists matters as much as price.

Diabetes and obesity · AstraZeneca (Forxiga), co marketed by Sun Pharma and Abbott

Dapagliflozin

India status
Generics launched
India timeline
Genus patent IN 205147 expired on 2 October 2020. Zydus launched Dapaglyn on 4 October 2020 at about one third of the brand price. AstraZeneca sued over a second patent valid to 15 May 2023, and the Delhi High Court refused it an interim injunction.
Indian makers
Zydus (Dapaglyn), Natco (Dapnat), Alkem, USV, Eris, Torrent, Intas, MSN, Micro Labs and others
Price control (NLEM 2022)
No
Approved uses
Type 2 diabetes, heart failure, chronic kidney disease
Common side effects
Genital fungal infections, urinary tract infections, dehydration. Rare ketoacidosis.
Evidence base
DECLARE-TIMI 58, DAPA-HF, DAPA-CKD
MRO View: A mature generic market. New entrants need a combination product or a channel edge to stand out.

Diabetes and obesity · MSD (Januvia, Janumet)

Sitagliptin

India status
Generics launched
India timeline
Patent expired in July 2022. Glenmark launched Sitazit on 7 July 2022 at Rs 10.50 to Rs 19.90 a tablet, about one third of the brand price.
Indian makers
Glenmark (Sitazit) first; close to 200 brands followed
Price control (NLEM 2022)
No
Approved uses
Type 2 diabetes
Common side effects
Upper respiratory infection, headache. Rare pancreatitis.
Evidence base
TECOS (heart safety)
MRO View: Crowded and price led. Growth comes from fixed dose combinations with metformin and SGLT2 drugs.

Diabetes and obesity · Novartis (Galvus)

Vildagliptin

India status
Generics launched
India timeline
Product patent IN 212815 expired on 9 December 2019. Generic launches followed within two days.
Indian makers
Zydus (Vinglyn, Rs 4.95 a tablet, about one sixth of the original price), Panacea Biotec (ViLACT) and others
Price control (NLEM 2022)
No
Approved uses
Type 2 diabetes
Common side effects
Headache, dizziness, tremor. Liver enzyme rise; label advises liver tests.
Evidence base
VERIFY (early combination with metformin)
MRO View: One of the earliest gliptin generics. Margins are thin and scale decides who earns.

Diabetes and obesity · Boehringer Ingelheim (Trajenta)

Linagliptin

India status
Generics launched
India timeline
Indian patent IN 243301 expired on 18 August 2023. In 2022 courts restrained four companies that had launched early. About 63 generic brands launched after expiry.
Indian makers
About 63 brands after expiry; Eris, MSN, Emcure and Optimus had launched in 2022 before expiry and were restrained
Price control (NLEM 2022)
No
Approved uses
Type 2 diabetes, including patients with kidney disease
Common side effects
Common cold symptoms, low blood sugar when used with sulfonylureas. Rare pancreatitis.
Evidence base
CARMELINA, CAROLINA (heart and kidney safety)
MRO View: The patent is gone. Watch for brands that use its kidney dosing advantage against other gliptins.

Diabetes and obesity · Mitsubishi Tanabe (patented globally, not in India)

Teneligliptin

India status
Generics launched
India timeline
Glenmark launched in India in July 2015 after local trials, at Rs 19.90 a tablet. Mankind launched Dynaglipt on 23 November 2015 and halved its price within a day. Within about a year, 30 companies sold 34 brands.
Indian makers
Glenmark (Ziten, Zita Plus), Mankind (Dynaglipt), Zydus, Eris, Intas and others
Price control (NLEM 2022)
Yes, 20 mg tablet
Approved uses
Type 2 diabetes
Common side effects
Low blood sugar when combined with sulfonylureas or insulin.
Evidence base
Indian trial in 237 patients across 36 centres
MRO View: A drug India developed its own market for. NLEM listing means a ceiling price applies.

Heart · Novartis (Vymada; Entresto globally); JB Pharma owns the Azmarda brand

Sacubitril + valsartan

India status
Generics launched
India timeline
Combination patents expired on 16 January 2023, and Glenmark launched Sacu V on 17 January 2023 at Rs 19 to Rs 45 a tablet. On 12 September 2025 the Patent Office revoked a later Novartis patent (IN 414518) on a supramolecular form.
Indian makers
Glenmark (Sacu V), Lupin (Valentas, Arnipin) and others; Natco, Torrent, MSN and Eris cleared to sell after the 2025 revocation
Price control (NLEM 2022)
No
Approved uses
Chronic heart failure with reduced ejection fraction
Common side effects
Low blood pressure, high potassium, reduced kidney function, angioedema. Not for use in pregnancy.
Evidence base
PARADIGM-HF
MRO View: The 2025 revocation removed the last block for several makers. Heart failure clinics are the target, so cardiology reach decides share.

Diabetes and obesity · Sanofi (Lantus)

Insulin glargine

India status
Biosimilars launched
India timeline
Wockhardt launched Glaritus in March 2009 and Biocon launched Basalog on 29 May 2009. Biocon added a prefilled pen, Basalog One, in September 2015.
Indian makers
Biocon (Basalog); Wockhardt (Glaritus)
Price control (NLEM 2022)
Yes, 100 IU/mL injection
Approved uses
Type 1 and type 2 diabetes (long acting basal insulin)
Common side effects
Low blood sugar, weight gain, injection site reactions.
Evidence base
Biocon's Indian studies; its glargine later won the first US interchangeable biosimilar approval (2021)
MRO View: A ceiling priced essential medicine. Devices and supply reliability count more than price.

Cancer · Roche (Herceptin)

Trastuzumab

India status
Biosimilars launched
India timeline
DCGI approved Biocon's biosimilar on 26 November 2013, the first biosimilar trastuzumab approved anywhere. It launched as CANMAb in February 2014.
Indian makers
Biocon (CANMAb) and Mylan, now Viatris (Hertraz), from the same joint development
Price control (NLEM 2022)
Yes, 440 mg/50 mL injection
Approved uses
HER2 positive breast cancer
Common side effects
Reduced heart function, infusion reactions, harm to the unborn baby.
Evidence base
Indian multi centre trial; global HERITAGE study
MRO View: A proven biosimilar market with a ceiling price. New entrants must compete on hospital tenders.

Immunology · AbbVie (Humira)

Adalimumab

India status
Biosimilars launched
India timeline
Zydus launched Exemptia on 9 December 2014, the first adalimumab biosimilar anywhere, at about one fifth of the originator price.
Indian makers
Zydus (Exemptia)
Price control (NLEM 2022)
No
Approved uses
Rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis
Common side effects
Serious infections including TB reactivation, injection site reactions.
Evidence base
Zydus Phase III in India
MRO View: TB screening is a must in India for anti TNF drugs. Patient support programmes help keep patients on therapy.

Cancer · Roche (Avastin)

Bevacizumab

India status
Biosimilars launched
India timeline
Reliance Life Sciences announced DCGI approval on 10 June 2016 and launched Bevacirel with Lupin; Hetero announced Cizumab on 27 June 2016.
Indian makers
Reliance Life Sciences with Lupin, Hetero
Price control (NLEM 2022)
No
Approved uses
Metastatic colorectal cancer (first approved use)
Common side effects
High blood pressure, bleeding, gut perforation, slow wound healing, protein in urine.
Evidence base
Indian approvals based on comparative trials
MRO View: A tender driven oncology market. Cost per vial and supply to cancer hospitals decide share.

Eye · Genentech and Novartis (Lucentis)

Ranibizumab

India status
Biosimilars launched
India timeline
Intas launched Razumab on 19 June 2015, the first ranibizumab biosimilar anywhere, about 25% cheaper than Lucentis.
Indian makers
Intas (Razumab) and others; India has five approved ranibizumab biosimilars
Price control (NLEM 2022)
No
Approved uses
Wet age related macular degeneration, diabetic macular oedema, macular oedema after vein occlusion
Common side effects
Eye pain, raised eye pressure, bleeding on the eye surface. Rare serious eye infection.
Evidence base
Head to head trial against Lucentis in Indian patients
MRO View: India approved a ranibizumab biosimilar years before Europe or the US. Retina specialists, not price, drive brand choice.

Bone health · Amgen (Prolia, Xgeva)

Denosumab

India status
Biosimilars launched
India timeline
Enzene (Alkem) received DCGI approval in August 2021. Zydus launched Zyrifa (120 mg) on 10 December 2025 at an MRP of Rs 12,495.
Indian makers
Enzene (Alkem), Zydus; a CDSCO panel accepted Intas's Phase I report in June 2025; CuraTeQ Biologics recommended for manufacture and marketing (60 mg) in November 2026
Price control (NLEM 2022)
No
Approved uses
Osteoporosis; preventing bone complications from cancer that has spread to bone
Common side effects
Low calcium, jaw bone damage (rare), back and limb pain. Fracture risk can rise after stopping.
Evidence base
Enzene’s Indian trial; Intas Phase I in healthy volunteers
MRO View: Two uses, two buyers: bone clinics and cancer hospitals. Makers need both channels.

Cancer · Bristol Myers Squibb (Opdyta in India, Opdivo globally)

Nivolumab

India status
Biosimilars launched
India timeline
Zydus got CDSCO approval in July 2024. The Delhi High Court lifted an injunction on 12 January 2026; Zydus launched Tishtha on 22 January 2026 (100 mg at Rs 28,950). The Supreme Court dismissed BMS's petition on 11 February 2026. The Indian patent expired on 2 May 2026.
Indian makers
Zydus (Tishtha)
Price control (NLEM 2022)
No
Approved uses
Several cancers including melanoma, lung and kidney cancer
Common side effects
Immune related inflammation of lungs, gut, liver, thyroid and skin; tiredness.
Evidence base
CheckMate programme
MRO View: The first nivolumab biosimilar anywhere. The court's public interest reasoning matters for every biologic patent case that follows.

Cancer · MSD (Keytruda)

Pembrolizumab

India status
Patent protected
India timeline
No biosimilar approved in India yet. The Indian patent runs to 2028. CDSCO expert panels cleared biosimilar trials by several Indian firms in 2025 and 2026.
Indian makers
Enzene, Hetero, Intas and Sun Pharma running Indian trials; Shilpa Biologicals and Zydus (ZRC 3323) filed trial protocols in October 2026; Zydus partner Formycon's FYB206 filing accepted for US FDA review in October 2026
Price control (NLEM 2022)
No
Approved uses
Many cancers including lung, melanoma, head and neck
Common side effects
Immune related inflammation of lungs, gut, liver, thyroid and skin; tiredness.
Evidence base
KEYNOTE programme
MRO View: The largest biologic opportunity ahead. Companies that clear Indian trials early will lead when patents end.

Cancer · AstraZeneca (Tagrisso)

Osimertinib

India status
Patent protected
India timeline
Indian patent IN 297581 runs to 2032. AstraZeneca won post grant oppositions by Natco and Sunshine Organics, and the Delhi High Court granted it a permanent injunction against an infringer.
Indian makers
None on the market; generic attempts restrained
Price control (NLEM 2022)
No
Approved uses
EGFR mutated non small cell lung cancer
Common side effects
Diarrhoea, rash, dry skin, nail changes. Rare lung inflammation and heart rhythm changes.
Evidence base
FLAURA, ADAURA
MRO View: Patents are holding. Entry before expiry means litigation risk, so most companies are waiting.

Infectious disease · Johnson & Johnson (Sirturo)

Bedaquiline

India status
Off patent
India timeline
Used in India's TB programme since 21 March 2016. The primary patent expired in July 2023. The Patent Office rejected a secondary patent in March 2023.
Indian makers
Lupin (WHO prequalified 100 mg tablet, December 2023)
Price control (NLEM 2022)
Yes, 100 mg tablet
Approved uses
Drug resistant tuberculosis, with other TB medicines
Common side effects
Nausea, joint pain, headache. Heart rhythm (QT) changes and liver enzyme rise.
Evidence base
C208 trial
MRO View: Demand is mostly government. Winning the national TB programme tender is the market.

Infectious disease · Gilead (Sovaldi)

Sofosbuvir

India status
Generics launched
India timeline
Gilead licensed Indian makers from September 2014. DCGI approved Natco and Hetero versions on 12 March 2015, each at Rs 19,900 for 28 tablets.
Indian makers
Natco (Hepcinat), Hetero (Sofovir), Cipla, Zydus, Mylan, Strides and other licensees
Price control (NLEM 2022)
Yes, 400 mg tablet
Approved uses
Chronic hepatitis C, with other antivirals
Common side effects
Tiredness, headache, nausea. Slow heart rate if taken with amiodarone; hepatitis B can flare.
Evidence base
NEUTRINO, FISSION
MRO View: A licence led market with ceiling prices. Volume depends on state hepatitis programmes.

Cancer · Pfizer (Ibrance)

Palbociclib

India status
Generics launched
India timeline
Indian patent expired on 10 January 2023. Sun Pharma launched the first generic on 11 January 2023. Generics cost about Rs 3,800 a month against over Rs 80,000 for the brand.
Indian makers
Sun Pharma (Paleno) first, BDR Pharma (BDPALBO); about 15 Indian companies producing or preparing
Price control (NLEM 2022)
No
Approved uses
HR positive, HER2 negative advanced breast cancer, with hormone therapy
Common side effects
Low white cell counts, infections, tiredness, nausea, hair thinning.
Evidence base
PALOMA trials
MRO View: A clear case of how fast prices fall after expiry. The same pattern is likely for other CDK4/6 drugs as patents end.

Cancer · Incyte; sold in India by Novartis (Jakavi)

Ruxolitinib

India status
Patent protected
India timeline
Jakavi was launched in India in 2013. Patent IN 269841 expires on 12 December 2026. On 24 September 2026 the Delhi High Court restrained Melody Healthcare from making or selling ruxolitinib, with the next hearing on 20 January 2027.
Indian makers
None on sale yet. Shilpa Medicare, Aurore Life Sciences and Melody Healthcare are under court orders not to sell before expiry.
Price control (NLEM 2022)
No
Approved uses
Myelofibrosis, polycythaemia vera, graft versus host disease
Common side effects
Low platelet count, anaemia, bruising, dizziness
Evidence base
COMFORT-I, COMFORT-II
MRO View: The first Indian launches can come in December 2026. Companies that have already been restrained have shown they are ready, so expect several brands within weeks.

Cancer · Pharmacyclics and Janssen (Imbruvica)

Ibrutinib

India status
Patent protected
India timeline
Patent IN 262968 runs into 2026. In December 2023 the Delhi High Court restrained six Indian companies from selling ibrutinib, and Emcure gave the court an undertaking on 13 May 2025.
Indian makers
None on sale yet. Natco, Hetero, BDR, Shilpa, Alkem and Laurus are restrained; Emcure has given an undertaking.
Price control (NLEM 2022)
No
Approved uses
Chronic lymphocytic leukaemia, mantle cell lymphoma, Waldenström macroglobulinaemia
Common side effects
Bleeding, atrial fibrillation, diarrhoea, infections
Evidence base
RESONATE, RESONATE-2
MRO View: At least seven Indian companies are waiting on one patent, so prices are likely to fall fast once it lapses.

Cancer · Novartis (Tafinlar)

Dabrafenib

India status
Patent protected
India timeline
The Indian patent runs to 4 May 2029. In August 2026 the Delhi High Court passed a decree based on an undertaking by Zydus.
Indian makers
None on sale. Zydus has undertaken not to launch while the patent is in force.
Price control (NLEM 2022)
No
Approved uses
BRAF V600 mutant melanoma and lung cancer, usually with trametinib
Common side effects
Fever, rash, tiredness, joint pain
Evidence base
COMBI-d, COMBI-v, COMBI-AD
MRO View: A 2029 date, now fixed by a court decree, gives Indian makers a clear planning window.

Cancer · Helsinn (Akynzeo)

Netupitant + palonosetron

India status
Patent protected
India timeline
The patent was granted on 23 March 2023 and is valid to 18 November 2030. An earlier challenge by Zydus was dismissed, and Intas was restrained in November 2026.
Indian makers
None on sale. Intas is restrained; Zydus lost its challenge.
Price control (NLEM 2022)
No
Approved uses
Preventing nausea and vomiting from cancer chemotherapy
Common side effects
Headache, constipation, tiredness
Evidence base
Phase III trials in cisplatin and anthracycline based chemotherapy
MRO View: Two failed attempts to enter show the patent is holding. The real opening is late 2030.

Rare disease · Roche (Evrysdi)

Risdiplam

India status
Generics launched
India timeline
Patent IN 334397 runs to 11 May 2035. In March 2025 the Delhi High Court refused Roche an interim injunction against Natco. Roche lost its appeal and the Supreme Court upheld the ruling.
Indian makers
Natco
Price control (NLEM 2022)
No
Approved uses
Spinal muscular atrophy
Common side effects
Fever, diarrhoea, rash
Evidence base
FIREFISH, SUNFISH
MRO View: A rare case of an Indian launch nine years before patent expiry, on the strength of a credible validity challenge.

Cancer · Novartis (Kisqali)

Ribociclib

India status
Patent protected
India timeline
A second Indian patent was granted in 2026 after a 15 year delay. Natco filed to revoke it in August 2026. On 28 September 2026 the Kerala High Court ruled on government use of the patent under Section 100 of the Patents Act.
Indian makers
None on sale. Natco is challenging the patent.
Price control (NLEM 2022)
No
Approved uses
HR positive, HER2 negative breast cancer
Common side effects
Low white cell count, nausea, QT prolongation, raised liver enzymes
Evidence base
MONALEESA-2, MONALEESA-3, MONALEESA-7, NATALEE
MRO View: The launch date depends on the revocation case and the government use question, not on a calendar date.

Heart · Bayer and MSD (Verquvo; Adverio in India)

Vericiguat

India status
Patent protected
India timeline
Patent IN 316570. Bayer won an interim injunction from the Delhi High Court in October 2026.
Indian makers
None on sale.
Price control (NLEM 2022)
No
Approved uses
Chronic heart failure with reduced ejection fraction after a recent worsening
Common side effects
Low blood pressure, anaemia
Evidence base
VICTORIA
MRO View: A small but growing heart failure market. Entry waits on the outcome of the infringement suit.

Heart · Bristol Myers Squibb and Pfizer (Eliquis)

Apixaban

India status
Off patent
India timeline
Patent IN 247381 expired on 17 September 2022. Before expiry the Delhi High Court restrained Cipla and Micro Labs from launching, and recorded a settlement with Indoco.
Indian makers
Cipla, Natco (Apigat), Micro Labs (Apivas), BDR and Indoco were all in court before expiry.
Price control (NLEM 2022)
No
Approved uses
Stroke prevention in atrial fibrillation, treating and preventing deep vein thrombosis and pulmonary embolism
Common side effects
Bleeding, anaemia, nausea
Evidence base
ARISTOTLE, AMPLIFY
MRO View: The main patent has gone, so the contest is now on price and doctor reach.

Heart · Bayer (Xarelto); Zydus sells a second brand as Bayer’s partner

Rivaroxaban

India status
Generics launched
India timeline
More than half a dozen generic rivaroxaban brands are on sale in India, many priced more than 50% below Xarelto.
Indian makers
Zydus, plus several other Indian brands
Price control (NLEM 2022)
No
Approved uses
Stroke prevention in atrial fibrillation, deep vein thrombosis and pulmonary embolism, coronary and peripheral artery disease with aspirin
Common side effects
Bleeding, anaemia
Evidence base
ROCKET AF, EINSTEIN DVT and PE, COMPASS
MRO View: A crowded generic market where the originator kept a foothold through a local partner brand.

Cancer · Bayer (Nexavar)

Sorafenib

India status
Generics launched
India timeline
Bayer got an Indian patent in 2008. On 9 March 2012 the Controller of Patents granted Natco India’s first compulsory licence, capping its price at Rs 8,800 for a month’s 120 tablets against Bayer’s Rs 2.8 lakh, with a 6% royalty to Bayer. The Supreme Court dismissed Bayer’s challenge in December 2014. The patent ran to 2020.
Indian makers
Natco (Sorafenat), Cipla (Soranib)
Price control (NLEM 2022)
No
Approved uses
Advanced kidney, liver and thyroid cancer
Common side effects
Hand and foot skin reaction, diarrhoea, high blood pressure, tiredness
Evidence base
SHARP, TARGET
MRO View: The case that set India’s rule on affordability. Any originator pricing far above local purchasing power still has to reckon with it.

Cancer · Bayer (Stivarga)

Regorafenib

India status
Generics launched
India timeline
The genus patent covering regorafenib expired on 12 January 2020. Bayer sued Natco on a later patent, and in July 2023 the Delhi High Court refused an interim injunction, noting that Bayer imported the drug at Rs 36,995 while Natco made it in India and sold it at Rs 9,900.
Indian makers
Natco (Regonat)
Price control (NLEM 2022)
No
Approved uses
Metastatic colorectal cancer, gastrointestinal stromal tumour, liver cancer
Common side effects
Hand and foot skin reaction, tiredness, high blood pressure, liver injury
Evidence base
CORRECT, GRID, RESORCE
MRO View: Courts weigh the price gap heavily when a later patent repeats a molecule from an expired one.

Cancer · Astellas and Pfizer (Xtandi)

Enzalutamide

India status
Generics launched
India timeline
On 8 November 2016 the Indian Patent Office refused the patent after pre grant oppositions by BDR, Fresenius Kabi and others. Astellas was then selling a month’s pack of 112 capsules at Rs 3.35 lakh. Zydus launched a generic at a 70% to 90% discount, and BDR later launched 80 mg tablets at Rs 24,480 a pack.
Indian makers
Zydus, BDR
Price control (NLEM 2022)
No
Approved uses
Prostate cancer, castration resistant and hormone sensitive
Common side effects
Tiredness, hot flushes, high blood pressure, falls; seizures are rare
Evidence base
AFFIRM, PREVAIL, ARCHES
MRO View: A refused patent opened the market fully. Competition is now on price and on oncologist reach.

Cancer · AstraZeneca and Kudos (Lynparza)

Olaparib

India status
Generics launched
India timeline
Patent IN 228720 was granted on 10 February 2009. The Delhi High Court permanently restrained Dr Reddy’s on 22 December 2023 and stopped Natco’s Bracanat on 1 March 2024. Zydus launched a generic in March 2024 and capped a year of treatment at Rs 3 lakh, against about Rs 72 lakh for the originator.
Indian makers
Zydus; Natco (Bracanat) and BDR (BDPARP) sold earlier and faced court action
Price control (NLEM 2022)
No
Approved uses
Ovarian, breast, pancreatic and prostate cancer with BRCA or related mutations
Common side effects
Anaemia, nausea, tiredness, vomiting
Evidence base
SOLO-1, OlympiAD, POLO, PROfound
MRO View: The price gap after generic entry, from Rs 72 lakh to Rs 3 lakh a year, shows how much demand was locked out.

Cancer · Eisai, with MSD (Lenvima)

Lenvatinib

India status
Generics launched
India timeline
Shilpa Medicare won approval and launched Lenshil in February 2020 at over 50% below the originator, whose average therapy cost was about Rs 1.90 lakh. BDR launched Bdfoie in October 2020 at Rs 1,620 for ten 4 mg capsules and Rs 2,970 for ten 10 mg capsules. Shilpa was later first in India with 12, 18 and 24 mg strengths.
Indian makers
Shilpa Medicare (Lenshil), BDR (Bdfoie)
Price control (NLEM 2022)
No
Approved uses
Thyroid, liver and kidney cancer; endometrial cancer with pembrolizumab
Common side effects
High blood pressure, diarrhoea, tiredness, protein in urine
Evidence base
SELECT, REFLECT, CLEAR
MRO View: New strengths that cut the pill count are how Indian makers compete once the price floor is reached.

Cancer · Roche (Perjeta)

Pertuzumab

India status
Biosimilars launched
India timeline
Zydus got conditional approval for its biosimilar on 4 April 2024 and permission to market on 27 June 2024, but the Delhi High Court temporarily restrained its sale on 9 July 2024 on Roche’s patents IN 268632 and IN 464646. Intas’s biosimilar was approved in December 2024. Enzene launched on 22 September 2025, sold by Alkem and Hetero.
Indian makers
Enzene (sold as Alkem Pertuza and Hetero Perzea), Intas; Zydus (Sigrima) and Dr Reddy’s (Womab) under the 2024 restraint
Price control (NLEM 2022)
No
Approved uses
HER2 positive breast cancer, with trastuzumab
Common side effects
Diarrhoea, hair loss, low white cell count, rash
Evidence base
CLEOPATRA, APHINITY, NeoSphere
MRO View: Roche holds no product patent on the molecule in India, so the fight is over later patents, and some biosimilars are already on sale.

Eye · Regeneron and Bayer (Eylea)

Aflibercept

India status
Biosimilars launched
India timeline
Biocon’s biosimilar was recommended by the expert committee in September 2025. Zydus launched Anyra, the first aflibercept 2 mg biosimilar developed in India, on 19 February 2026 under a licence from Regeneron and Bayer. In April 2026 Bayer cut the Eylea price by about 44%, from Rs 53,141 to Rs 29,998.
Indian makers
Zydus (Anyra), Biocon (Yesafili, recommended)
Price control (NLEM 2022)
No
Approved uses
Wet age related macular degeneration, diabetic macular oedema, macular oedema after retinal vein occlusion, diabetic retinopathy, myopic choroidal neovascularisation
Common side effects
Eye pain, bleeding on the eye surface, raised eye pressure; eye infection is rare
Evidence base
VIEW 1, VIEW 2, VIVID, VISTA
MRO View: The originator cut its price within two months of the first biosimilar, a sign of how price sensitive the retina market is.

Infectious disease · Gilead (Vemlidy)

Tenofovir alafenamide

India status
Generics launched
India timeline
In July 2014 Gilead licensed tenofovir alafenamide through the Medicines Patent Pool so that makers in India and China could produce it. Mylan launched HepBest on 7 December 2017, and Natco launched Tafnat on 18 December 2017 at Rs 1,900 for 30 tablets, made under licence.
Indian makers
Mylan (HepBest), Natco (Tafnat)
Price control (NLEM 2022)
Yes
Approved uses
Chronic hepatitis B; part of HIV combinations
Common side effects
Headache, nausea, tiredness
Evidence base
Studies 108 and 110
MRO View: Licensed generics arrived within about a year of the global launch, which kept India priced far below the originator from the start.

Infectious disease · ViiV Healthcare (Tivicay)

Dolutegravir

India status
Generics launched
India timeline
People living with HIV filed oppositions to ViiV’s Indian patent applications in February 2016. Generic dolutegravir became available in India in February 2017 under voluntary licences from ViiV and the Medicines Patent Pool. NLEM 2022 added it as one of four patented medicines on the list.
Indian makers
Indian licensees of ViiV and the Medicines Patent Pool
Price control (NLEM 2022)
Yes
Approved uses
HIV infection, with other antiretrovirals
Common side effects
Sleep problems, headache, weight gain
Evidence base
SPRING-2, SINGLE, FLAMINGO
MRO View: Price control on a patented drug is rare in India. Dolutegravir shows how licensing and the essential list can work together.

Infectious disease · Bristol Myers Squibb (Daklinza)

Daclatasvir

India status
Generics launched
India timeline
BMS licensed daclatasvir royalty free through the Medicines Patent Pool in November 2015. Natco became the first Indian company with DCGI approval on 14 December 2015 and launched Natdac at Rs 6,000 for 28 tablets of 60 mg and Rs 4,000 for 30 mg. Hetero was approved the same month. It is on NLEM 2022 as a patented medicine.
Indian makers
Natco (Natdac), Hetero, Cipla, Mylan, Zydus
Price control (NLEM 2022)
Yes
Approved uses
Chronic hepatitis C, with sofosbuvir
Common side effects
Headache, tiredness, nausea; slow heart rate if taken with amiodarone
Evidence base
ALLY-3, AI444-040
MRO View: Hepatitis C in India became a volume market once licensed generics and price control both applied.

Cancer · Roche (MabThera)

Rituximab

India status
Biosimilars launched
India timeline
Dr Reddy’s launched Reditux on 30 April 2007, the first rituximab biosimilar anywhere, at about half the originator price. Intas, Hetero (Maball) and Cadila Pharmaceuticals (Ritucad) followed. Rituximab is under price control through the essential medicines list.
Indian makers
Dr Reddy’s (Reditux), Intas (Mabtas), Hetero (Maball), Cadila Pharmaceuticals (Ritucad)
Price control (NLEM 2022)
Yes
Approved uses
Non Hodgkin lymphoma, chronic lymphocytic leukaemia, rheumatoid arthritis
Common side effects
Infusion reactions, infections, low white cell count; hepatitis B can flare
Evidence base
CLL8, REFLEX
MRO View: India was the first market for a rituximab biosimilar, years before Europe or the US.

Cancer · Roche (Kadcyla)

Trastuzumab emtansine

India status
Biosimilars launched
India timeline
Zydus launched Ujvira on 24 May 2021, the first biosimilar of trastuzumab emtansine anywhere, at Rs 32,495 for a 100 mg vial against Rs 1,59,225 for the originator.
Indian makers
Zydus (Ujvira)
Price control (NLEM 2022)
No
Approved uses
HER2 positive breast cancer, after trastuzumab or with residual disease after surgery
Common side effects
Low platelet count, raised liver enzymes, tiredness, nerve damage
Evidence base
EMILIA, KATHERINE
MRO View: An antibody drug conjugate is among the hardest products to copy. One Indian maker did it at an 80% discount.

Immunology · Amgen and Pfizer (Enbrel)

Etanercept

India status
Biosimilars launched
India timeline
Cipla launched Etacept on 17 April 2013, made by Shanghai CP Guojian, at about 30% below Enbrel. Intas launched Intacept on 27 March 2015, the first etanercept made in India, at about half the price of imported Enbrel.
Indian makers
Cipla (Etacept), Intas (Intacept)
Price control (NLEM 2022)
No
Approved uses
Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, juvenile arthritis, plaque psoriasis
Common side effects
Injection site reactions, infections, reactivation of tuberculosis
Evidence base
TEMPO, COMET
MRO View: An early example of an Indian company importing a biosimilar before local makers caught up.

Kidney · Amgen (Aranesp)

Darbepoetin alfa

India status
Biosimilars launched
India timeline
Dr Reddy’s launched Cresp on 9 August 2010, the first darbepoetin alfa biosimilar anywhere, and said patients switching from Aranesp could save up to 85%. Hetero launched its own version in June 2014.
Indian makers
Dr Reddy’s (Cresp), Hetero
Price control (NLEM 2022)
No
Approved uses
Anaemia from chronic kidney disease and from chemotherapy
Common side effects
High blood pressure, blood clots, headache
Evidence base
TREAT
MRO View: A longer acting option in a market crowded with cheap epoetin biosimilars.

Cancer · Amgen (Neulasta)

Pegfilgrastim

India status
Biosimilars launched
India timeline
Intas won Indian approval for Neupeg in August 2007, the first pegfilgrastim biosimilar in India. Dr Reddy’s Peg-grafeel was approved in May 2010 and Lupin’s version in September 2013.
Indian makers
Intas (Neupeg), Dr Reddy’s (Peg-grafeel), Lupin
Price control (NLEM 2022)
No
Approved uses
Reducing infection risk from low white cell counts during chemotherapy
Common side effects
Bone pain, injection site pain; spleen rupture is rare
Evidence base
Phase III trials against daily filgrastim
MRO View: Indian makers had this market a decade before Europe saw its first biosimilar.

Bone health · Eli Lilly (Forteo)

Teriparatide

India status
Biosimilars launched
India timeline
Intas was approved in November 2010, followed by Cadila Healthcare and USV in August 2012. Cadila Pharmaceuticals launched NuPTH in October 2020, and Enzene won approval on 4 February 2021, sold through Alkem.
Indian makers
Intas, Zydus, USV, Cadila Pharmaceuticals (NuPTH), Enzene with Alkem
Price control (NLEM 2022)
No
Approved uses
Osteoporosis with high fracture risk
Common side effects
Nausea, dizziness, leg cramps, raised calcium
Evidence base
Fracture Prevention Trial, VERO
MRO View: A steady, multi maker market where device quality and doctor reach decide share.

Diabetes and obesity · Novo Nordisk (NovoRapid)

Insulin aspart

India status
Biosimilars launched
India timeline
USV and Biogenomics launched Insuquick in November 2023, the first insulin aspart biosimilar in India. Wockhardt filed its own aspart with the DCGI in October 2024, when the Indian aspart market was over Rs 260 crore with only two players.
Indian makers
USV (Insuquick, with Biogenomics); Wockhardt filed
Price control (NLEM 2022)
No
Approved uses
Mealtime insulin for type 1 and type 2 diabetes
Common side effects
Low blood sugar, injection site reactions, weight gain
Evidence base
Phase III trials against regular human insulin
MRO View: Rapid acting analogues are where the next insulin price fall in India is likely to come.

Immunology · Pfizer (Xeljanz)

Tofacitinib

India status
Generics launched
India timeline
The Indian Patent Office rejected Pfizer’s patent application in 2011 and rejected it again later. Generic tofacitinib was in wide use for rheumatoid arthritis in India by 2021.
Indian makers
Cipla (Tofajak), MSN (Tofadoz)
Price control (NLEM 2022)
No
Approved uses
Rheumatoid arthritis, psoriatic arthritis, ulcerative colitis
Common side effects
Infections, shingles, raised cholesterol, blood clots
Evidence base
ORAL Standard, ORAL Surveillance
MRO View: A refused patent made an oral alternative to injected biologics widely affordable.

Heart · AstraZeneca (Brilinta)

Ticagrelor

India status
Generics launched
India timeline
The DCGI approved Brilinta in May 2012 and AstraZeneca launched it in October 2012. AstraZeneca later sued MSN over its Tiare brand on patents IN 209907, IN 247984 and IN 272674, and the Delhi High Court lifted restraining orders on Micro Labs, Dr Reddy’s and Natco after finding a credible challenge to the patents.
Indian makers
MSN (Tiare), Torrent (Torplat), USV (Ticaspan)
Price control (NLEM 2022)
No
Approved uses
Acute coronary syndrome and prevention after a heart attack, with aspirin
Common side effects
Bleeding, breathlessness, slow heart rate
Evidence base
PLATO, PEGASUS-TIMI 54
MRO View: A credible validity challenge was enough to open a blockbuster heart drug to Indian brands.

Uses and side effects are summarised in plain words from the approved prescribing information. This is not medical advice; check the full prescribing information. Sales and prescription figures are not shown because no official source publishes them by molecule. "Indian makers" lists companies that announced launches or approvals and is not a complete count.

Get the monthly India tracker updateNew state data and new plant announcements in one short email, once a month.

One email a month. Reply to any email to unsubscribe. Privacy policy

Frequently asked questions

Which major medicines went off patent in India in 2026?

Semaglutide went off patent on 20 March 2026, and Natco, Sun Pharma, Dr Reddy's, Zydus, Glenmark and others launched generics. Zydus also launched Tishtha, a nivolumab biosimilar, on 22 January 2026 after a Delhi High Court ruling.

Which medicines in this tracker are under price control?

Teneligliptin, insulin glargine, trastuzumab, bedaquiline and sofosbuvir are in the National List of Essential Medicines 2022, so ceiling prices apply.

Which medicines here are still patent protected in India?

Tirzepatide, pembrolizumab and osimertinib. Indian companies are preparing biosimilars of pembrolizumab for when its patents end.

Download this tracker as Excel

Every row on this page in one spreadsheet, ready to filter and share with your team. Free for internal use.

We use your details only to share related MRO research. See our privacy policy.

Need the numbers behind this tracker?

We map patent timelines, competing makers and pricing for companies planning a launch in India.